Literature DB >> 23252532

Enzalutamide in prostate cancer after chemotherapy.

Alfredo Berruti, Daniele Generali, Marco Tampellini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23252532     DOI： 10.1056/NEJMc1212940

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.

Authors:  Benyi Li; Aijing Sun; Wencong Jiang; J Brantley Thrasher; Paul Terranova
Journal:  Am J Clin Exp Urol       Date:  2014-10-02

Review 2.  Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice.

Authors:  Giandomenico Roviello; Martina Catalano; Carlotta Ottanelli; Roberta Giorgione; Virginia Rossi; Elisabetta Gambale; Chiara Casadei; Ugo De Giorgi; Lorenzo Antonuzzo
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

3.  High-throughput cell-based compound screen identifies pinosylvin methyl ether and tanshinone IIA as inhibitors of castration-resistant prostate cancer.

Authors:  Kirsi Ketola; Miro Viitala; Pekka Kohonen; Vidal Fey; Zoran Culig; Olli Kallioniemi; Kristiina Iljin
Journal:  J Mol Biochem       Date:  2016-03-30

Review 4.  Androgen receptor: structure, role in prostate cancer and drug discovery.

Authors:  M H Eileen Tan; Jun Li; H Eric Xu; Karsten Melcher; Eu-leong Yong
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.